- Home
- CNC vs DVAX Comparison
CNC vs DVAX Comparison
Compare CNC & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNC | DVAX |
|---|---|---|
| Founded | 1984 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.7B | 1.3B |
| IPO Year | 2001 | 2004 |
Fundamental Metrics
Financial Performance| Metric | CNC | DVAX |
|---|---|---|
| Price | $41.86 | $15.38 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 17 | 5 |
| Target Price | ★ $40.06 | $26.50 |
| AVG Volume (30 Days) | ★ 5.6M | 3.9M |
| Earning Date | 02-03-2026 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $167,680,000,000.00 | $330,514,000.00 |
| Revenue This Year | $32.55 | $24.63 |
| Revenue Next Year | $0.21 | $15.85 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 14.57 | ★ 26.73 |
| 52 Week Low | $25.08 | $9.20 |
| 52 Week High | $66.81 | $15.49 |
Technical Indicators
Market Signals| Indicator | CNC | DVAX |
|---|---|---|
| Relative Strength Index (RSI) | 66.69 | 88.85 |
| Support Level | $38.58 | $10.78 |
| Resistance Level | $40.15 | $15.43 |
| Average True Range (ATR) | 1.06 | 0.16 |
| MACD | 0.11 | 0.46 |
| Stochastic Oscillator | 93.70 | 97.74 |
Price Performance
Historical ComparisonAbout CNC Centene Corporation
Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of December 2024, mostly in Medicaid (about 60% of membership), the individual exchanges (about 20%), and Medicare (about 5%). The company also has a military contract and provides Medicare Part D pharmaceutical plans.
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.